Global Mesenchymal Stem Cells Market; By Product & Services; By Type (Autologous & Allogeneic); By Source of Isolation (Bone Marrow, Cord Blood, & Others); By Indication (Bone and Cartilage Repair, & Other Indications); By Application (Disease Modelling, Tissue Engineering, & Other Applications); By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast: 2023-2032

Global Mesenchymal Stem Cells Market Report Overview

The Global Mesenchymal Stem Cells Market size is expected to be worth around USD 7,715.50 million by 2032 from USD 2,668.80 million in 2022, growing at a CAGR of 11.20% during the forecast period from 2022 to 2032.

The mesenchymal stem cells market is experiencing rapid growth due to the exponential increase in Mesenchymal-Stem Cell (MSC) research and its implications for regenerative medicines. In the forecast period, investments in the MSC market space are expected to be driven by the constantly changing landscape of stem cell and the adoption of these therapies. Large-scale operational entities have begun to target small and emerging players in an attempt to increase their market presence.

Global Mesenchymal Stem Cells Market Share

Products & Services Analysis

In terms of Products and Services, the Products segment dominated this market, accounting for 80.3% of total revenues in 2021. The Cell and Cell Lines segment is a major contributor to this market’s revenues. Several industry players are actively seeking to tap into this market space. They have undertaken various initiatives, including new product development and business expansion strategies. These market players provide mesenchymal stem cell and cell lines for research applications.

The Kits, Media, and Reagents segment is expected to experience the fastest growth rate at 12.1%, between the forecast period 2023-2032. A key factor driving this segment’s rapid growth is the expansion of product lines by its competitors. Researchers from China created a fully chemically defined medium, NBVbe, that allows for the isolation of human MSCs in March 2020. This product will aid in the optimization of MSC media, molecular characterization, and clinical applications.

MSC workflows have made significant revenue gains through the continuous improvement of cryopreservation and mesenchymal stem cells culture. In 2021, the Culture and Cryopreservation Workflows segment accounted for 46.5% of all revenue. This can be attributed to cell culture and cryopreservation techniques, which are essential to successful transitional research as well as basic research related to mesenchymal stem cells.

Type Analysis

With respect to Type, the Allogeneic Mesenchymal Stem Cells (MSCs) segment accounted for 57.8% of total revenues in 2021. Allogeneic mesenchymal and allogeneic MSCs have a high safety profile in clinical applications. The implantation of allogeneic MSCs will be a revolutionary cell-based therapeutic method due to their low immunogenicity and immunosuppressive property. This results in a decreased immune response which is a contributing factor to the success rate of allogeneic MSCs implantations.

However, autologous mesenchymal and stem cell technology has seen many advances over the years. This segment is forecast to grow at a 12.3% CAGR. Many studies have been conducted with autologous MSCs to treat various chronic diseases.

Source of Isolation Analysis

With regards to the Source of Isolation, the Bone Marrow segment accounted for 28.6% of total revenues in 2021. Mesenchymal stem cell isolation is made possible by the bone marrow. These cells have widespread applications and can differentiate into bone, cartilage, tendons, and fibroblasts. They also have multi-lineage differentiation capabilities and can be differentiated into cardiac, muscle, fat cells, and endothelial cell types. A December 2018 article stated that bone marrow aspirates taken from the pelvis are the most commonly used source for MSCs in clinical trials. This is expected to lead to the segment’s dominance, between the forecast period 2023-2032.

Adipose-derived mesenchymal stem cells have occupied the second spot in this market, in terms of revenue share. This segment is forecast to grow at an 11.9% CAGR over the forecast period. These multipotent mesenchymal cells are capable of expressing multiple functions, including isolation, expansion, and growth, as well as robust cell concentration. These cells have unique properties that make them more attractive than other mesenchymal stem cell types. The use of autologous MSCs derived from adipose is also promising for organs that have been damaged or injured by disease or other factors, and for regenerative medicine.

Indication Analysis

The mesenchymal stem cell market was dominated by the Cardiovascular Diseases segment, which accounted for 25.0% of the total revenue share in 2021. Pre-clinical research has shown that mesenchymal stem cell transplantation improves cardiovascular repair. This has increased the penetration of MSCs for cardiovascular disease indications. MSCs have properties that promote angiogenesis, increase apoptosis resistance, and promote differentiation of myocardial cell lines.

A meta-analysis and systematic review published in May 2019 found that mesenchymal stem cell treatment is an effective treatment for heart failure. These growth drivers will likely have a positive impact on segment growth over the next few years. Bone marrow-derived mesenchymal stem cells have been shown to undergo differentiation in vitro to form cartilage, fat, and bone.

This technology has been widely used in clinical applications related to Graft versus Host Disease, (GvHD) and contributed to the highest growth rate at 16.3%, between the forecast period 2023-2032. MSCs have been a key player in the development of cell therapies for oncology.

Application Analysis

In 2021, the Disease Modeling segment accounted for the largest revenue share in the mesenchymal stem cells market. It accounted for 38.4% of total revenues. The ideal tool for pathological research is the use of cellular disease models that are patient-specific MSCs. As a disease modeling tool, mesenchymal stem cell models derived from patient-induced pluripotent stem cells can be used. Research studies are increasingly using mesenchymal stem cells models to study the mechanisms behind chronic disorders. MSCs can also be used to assess non-hematological mesenchymal tumors like sarcomas. This is a major factor that has helped this segment gain prominence.

The Tissue Engineering segment is anticipated to grow at a 12.4% CAGR. A promising therapeutic approach in tissue engineering using mesenchymal stem cells has emerged. These types of cells are widely used due to their ability to expand, self-renew, and lower tumorigenic potential. In recent years, this market has indexed plenty of demand for stem cell encapsulation techniques.

Key Market Segments

By Product & Services

• Products
  • Workflow Type (Cell Sourcing & Isolation, Differentiation, Culture & Cryopreservation, Characterization)
  • Product Type (Kits, Media, & Reagents, Cells & Cell Lines, Others)
• Services

By Type

• Allogeneic
• Autologous

By Source of Isolation

• Bone Marrow
• Peripheral Blood
• Cord Blood
• Fetal Liver
• Fallopian Tube
• Adipose Tissues

By Indication

• Bone and Cartilage Repair
• Inflammatory and Immunological Diseases
• Cardiovascular Disease
• Liver Diseases
• GvHD
• Cancer
• Other Indications

By Application

• Disease Modelling
• Stem Cell Banking
• Drug Development & Discovery
• Toxicology Studies
• Tissue Engineering
• Other Applications

Market Dynamics

Mesenchymal stem cells market growth is expected to be accelerated by a strong pipeline of mesenchymal-derived products and emerging applications of mesenchymal cells. As of 2019, 10 products based on mesenchymal stem cell-derived products had been approved by regulatory agencies around the globe. A large number of companies are also exploring the potential for MSCs to be used as therapeutics in the development of treatment for inflammatory disorders, which is expected to boost market growth prospects.

Takeda/TiGenix’s phase-3 clinical trial includes MSCs to treat complex perianal fistulas of Crohn’s disease. This clinical trial is currently the most successful in its late stage. These factors will likely increase the use of MSC products by key market entities and intensify market competition in the process. The recent COVID-19 pandemic has prompted industry and scientific participants to focus their attention on the development of MSC-based therapies. MSCs have immunomodulating properties that can prevent COVID-19-related respiratory infections.

Most mesenchymal stem cells are used in research and clinical settings. Commercial applications of cell therapies have a smaller penetration. This can be attributed to the inability to standardize and regulate stem cell therapies, as well as ethical and safety concerns regarding human MSCs. To maintain market growth, it is imperative that regulations and standardization are improved in the mesenchymal stem cell industry.

Regional Analysis

North America held the largest share by geographic region, accounting for an annual growth rate of 48.2% of total revenues in 2021. Numerous clinical trials are being conducted to determine if mesenchymal-derived stem cells are safe and effective as viable treatments for a variety of life-threatening and complex diseases. The U.S. is home to many major companies involved in the commercialization and supply of MSCs. These factors have helped to make this region the dominant market.

European countries will be able to adopt MSCs if they have a strong research base that can evaluate the potential effects of clinical-scale manufacturing of mesenchymal cells. This is in addition to better funding programs from different public and private agencies. This space will be dominated by countries in the Asia-Pacific region.

Stem cell therapy has been growing in popularity due to limited financial support and access to healthcare in the Asia Pacific. MSCs are accepted in this region due to their low operating costs and large population figures. China is also known as the global hub for gene and cell therapy development.

Key Regions and Countries Covered in This Report

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis

In the competitive landscape, to maintain their respective market position, industry players are focusing on expanding their offerings by undertaking extensive R&D initiatives. The major players are seeking to form alliances and partnerships that will help them expand their existing product portfolios.

Due to the recent COVID-19 pandemic, many academic and research institutes have focused their efforts on developing a treatment regimen using mesenchymal-derived stem cells product. These advancements in stem cell therapies are further expected to proliferate the demand for MSCs.

Market Key Players

• Thermo Fisher Scientific Inc.
• Cell Applications Inc.
• Axol Biosciences Ltd.
• BrainStorm Cell Therapeutics Inc.
• Bayer AG
• BlueRock Therapeutics
• Cytori Therapeutics Inc.
• Cyagen Biosciences Inc.
• STEMCELL Technologies Inc
• ScienCell Research Laboratories
• Celprogen Inc.
• Genlantis Inc.
• Stemedica Cell Technologies Inc.
• Merck KGaA
• Lonza AG
• Other Key Players